According to the results of a comparative trial at Clayton Research Institute in St. Louis, Missouri, single-day famciclovir (1000 mg twice daily) was as effective and safe as 3-day valacyclovir (500 mg administered twice daily) for the treatment of genital herpes. Thus, it represents a more convenient medication for immuno-competent adults facing the problem of recurrent genital herpes. An effective short-course treatment can reduce the unwanted sequelae related to recurrences considerably. Novartis, the maker of famciclovir (brand name – Famvir), supported the study.